A patient has a positive screening for left ventricular heart failure; what is the next step in evaluation and management?

Confirm the Diagnosis with Echocardiography and Natriuretic Peptides

After a positive heart failure screen, immediately obtain an echocardiogram to assess left ventricular ejection fraction (LVEF) and measure natriuretic peptides (BNP or NT-proBNP) to confirm the diagnosis and guide initial management.

Diagnostic Confirmation Steps

The next steps depend on establishing both structural heart disease and the specific HF phenotype:

1. Echocardiography (Essential First Step)

• Measure LVEF to classify HF type 1, 2:
  • HFrEF: LVEF <40%
  • HFmrEF: LVEF 41-49%
  • HFpEF: LVEF ≥50%
• Assess left ventricular wall thickness (look for ≥14 mm, which raises suspicion for cardiac amyloidosis, especially if there's discordance between wall thickness and QRS voltage on ECG) 2
• Evaluate diastolic function and chamber sizes

2. Natriuretic Peptide Testing

• Obtain BNP or NT-proBNP levels to confirm diagnosis 3, 4
• Critical caveat: These levels vary significantly by age, sex, body weight, atrial fibrillation, and chronic kidney disease 3
• Obesity can falsely lower natriuretic peptide levels, potentially underestimating disease severity 5
• Elevated levels provide both diagnostic confirmation and prognostic information 4

3. Assess Symptom Burden

• Use Kansas City Cardiomyopathy Questionnaire (KCCQ) to quantify health status 6, 7
• KCCQ-OS <80 correlates with NYHA class II-IV symptoms 6
• This helps prioritize treatment intensity and monitor response

4. Screen for Cardiac Amyloidosis (If Indicated)

If you find LV wall thickness ≥14 mm, especially with low QRS voltage, fatigue, dyspnea, edema, or coexisting conditions like carpal tunnel syndrome, spinal stenosis, or polyneuropathy, immediately screen for amyloidosis 2:

• Serum and urine immunofixation electrophoresis
• Serum free light chains
• Serum and urine monoclonal light chain assessment

Management Based on LVEF Classification

For HFrEF (LVEF <40%)

Initiate guideline-directed medical therapy (GDMT) immediately 1, 8:

• Quadruple therapy is now standard:
  • ACE inhibitor/ARB or ARNI (sacubitril-valsartan)
  • Beta blocker
  • Mineralocorticoid receptor antagonist (spironolactone/eplerenone)
  • SGLT2 inhibitor

For HFmrEF (LVEF 41-49%)

Consider the same GDMT as HFrEF, as subgroup analyses show benefit 1:

• Beta blockers reduce mortality (BBmeta-HF analysis of 575 patients)
• Sacubitril-valsartan (PARAGON-HF subgroup with LVEF 45-57%)
• Candesartan (CHARM trials, 1,322 patients)
• Spironolactone, especially with poorly controlled hypertension (TOPCAT subgroup)
• Plan repeat echocardiography to track LVEF trajectory and adjust therapy 1

For HFpEF (LVEF ≥50%)

• SGLT2 inhibitors have demonstrated benefit 8
• GLP-1 receptor agonists for obesity management 8
• Aggressive comorbidity management (hypertension, diabetes, atrial fibrillation)

Common Pitfalls to Avoid

1. Don't stop GDMT if LVEF improves (HFimpEF): 40% of patients relapse within 6 months after medication withdrawal 1. Continue all HF medications even if the patient becomes asymptomatic and LVEF improves to >40% 1, 2.

2. Don't rely solely on natriuretic peptides in obese patients: They may be falsely low despite significant disease 5

3. Don't miss cardiac amyloidosis: The combination of HFpEF, increased wall thickness, and low QRS voltage should trigger immediate screening 2

4. Don't use a single natriuretic peptide threshold for all patients: Adjust interpretation based on age, sex, renal function, and atrial fibrillation 3

5. For intermediate probability cases (especially HFpEF): Consider exercise stress echocardiography or invasive hemodynamic testing, as noninvasive tools have limited sensitivity to rule out HFpEF 5